Summary
This 8-K filing from DexCom, Inc. (DXCM) on March 2, 2026, primarily reports on the return of Kevin R. Sayer to his role as Executive Chairman of the Board, effective March 2, 2026, after a temporary leave of absence. Mr. Sayer's transition from CEO to Executive Chairman was previously announced, and his return signifies a continuation of his leadership and strategic guidance for the company. This filing also details the new compensation arrangement for his role as Executive Chairman.
Key Highlights
- 1Kevin R. Sayer has returned to his position as Executive Chairman of the Board, effective March 2, 2026.
- 2Mr. Sayer was on a temporary leave of absence that began on September 14, 2025.
- 3Upon his return, Mr. Sayer resumed his duties and responsibilities as Executive Chairman.
- 4Mark Foletta has resumed his duties as Lead Independent Director.
- 5Mr. Sayer's new compensation includes an annual base salary of $610,000.
- 6He will receive restricted stock units valued at $2,350,000, vesting fully on March 8, 2027.
- 7Mr. Sayer will continue to participate in standard employee benefit plans but is no longer eligible for the Severance & Change in Control Plan as an executive officer.
Frequently Asked Questions
The main purpose of this filing is to announce the return of Kevin R. Sayer to his role as Executive Chairman of the Board after a temporary leave of absence and to detail his updated compensation agreement for this role.
Mr. Sayer took a temporary leave of absence starting September 14, 2025, and returned on March 2, 2026.
His compensation includes an annual base salary of $610,000 and restricted stock units with a fair value of $2,350,000, which vest in full on March 8, 2027, contingent on his continued service.
Yes, in addition to the new restricted stock units, his previously granted equity awards will continue to vest according to their original terms. He is also eligible to participate in DexCom's executive benefit plans.